Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22265089 | 0.83 | ACACB (0.34) | CYP1A2NAMPTACACB | |
| SCHEMBL22265097 | 0.81 | F2R (0.34) | CYP1A2NAMPTACACB | |
| SCHEMBL28056849 | 0.81 | ACACB (0.36) | CYP1A2NAMPTACACB | |
| SCHEMBL5163521 | 0.80 | MGAM (0.44) | NAMPTALDH1A1MAPTMEN1RAB9A | |
| SCHEMBL29551483 | 0.79 | F2R (0.33) | NAMPTALDH1A1MAPTGABRPGABRD | |
| SCHEMBL27965018 | 0.79 | FBP1 (0.33) | NAMPTALDH1A1MAPTGABRPGABRD | |
| SCHEMBL354704 | 0.79 | — | — | |
| SCHEMBL4282448 | 0.77 | FBP1 (0.55) | NAMPTACACBTSHRGAA | |
| SCHEMBL28204819 | 0.77 | GABRA1 (0.42) | ALDH1A1MAPTMEN1NPC1RAB9A | |
| SCHEMBL9124321 | 0.75 | KMT2A (0.52) | CYP1A2NAMPTMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184954-B | Degradable material added with starch | 福建德绿新材料科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118184954-A | Degradable material added with starch | 福建德绿新材料科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117396465-A | Novel oxazole derivative for preventing or treating allergic diseases and pharmaceutical composition containing the same | 阿斯克里斯有限公司 | 2024-01-12 | — | — | CN | claimed |
| WO-2026103793-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577211-B2 | Probenecid compounds for the treatment of inflammasome-mediated lung disease | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-03-17 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4681712-A2 | PROCESS FOR THE PRODUCTION OF FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-4126854-B1 | PROCESS FOR THE PRODUCTION OF FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655284-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| WO-2007093901-A1 | 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS | PFIZER LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| CN-101010323-A | Bicyclononene derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-01 | — | — | CN | disclosed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006133216-A2 | 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-6069132-A | PYRIMIDOPHOSOHAZOLE RING SYSTEM OF GIVEN STRUCTURE, THE TRIVALENT PHOSPHORUS OF THE RING SUBSTITUTED WITH VARIOUS GROUPS; NEW CLASS OF PHOSPHORUS CONTAINING HETEROCYCLES WITH APPLICATION IN MEDICAL, AGRICULTURAL AND INDUSTRIAL USE | ARONEX PHARMACEUTICALS, INC. | 2000-05-30 | — | — | US | disclosed |
| WO-1999008688-A1 | PHOSPHAZOLE-CONTAINING NUCLEOSIDE ANALOGS, RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN IN VITRO MEDICINAL TREATMENTS | ARONEX PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| US-4785012-A | OXAZOLE DERIVATIVES CONTAINING ALCOHOLS OR ESTERS | SYNTEX CORPORATION (US) | 1988-11-15 | — | — | US | disclosed |
| US-4039554-A | FORAMIDOESTERS, HYDROXYACETONE, DYES, PESTICIDES, VITAMINS | BASF AKTIENGESELLSCHAFT (DT) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CYP1A2 4592/4885NAMPT 3507/4885ALDH1A1 4348/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CYP1A2 2456/4885NAMPT 2728/4885ALDH1A1 3721/4885 |
| US-12577211-B2 | Probenecid compounds for the treatment of inflammasome-mediated lung disease | NLRP3, NLRP1, TLR4 | CYP1A2 4044/4885NAMPT 3960/4885ALDH1A1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.